Search results
Results from the WOW.Com Content Network
NEW YORK (Reuters) -Martin Shkreli, known for once hiking the price of a life-saving drug more than 4,000%, cannot return to the pharmaceutical industry after a federal appeals court on Tuesday ...
The U.S. Supreme Court declined on Monday to hear former pharmaceutical company CEO Martin Shkreli's challenge to a $64.6 million financial penalty imposed by a judge after he raised a lifesaving ...
Martin Shkreli (/ ˈ ʃ k r ɛ l i /; born March 17, 1983) is an American investor and businessman.Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, the co-founder and former CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals, and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.
Martin Shkreli must return $64.6 million in profits he and his former company reaped from jacking up the price and monopolizing the market for a lifesaving drug, a federal judge ruled Friday while ...
The Federal Trade Commission on Friday asked that notorious “pharma bro” Martin Shkreli be held in contempt of court for forming a new drug company in violation of a judge’s ban on the ...
Shkreli, 36, had been appealing his August 2017 conviction on two securities fraud counts and one conspiracy count. 'Pharma Bro' Martin Shkreli to stay behind bars, loses appeal of conviction Skip ...
Martin Shkreli, the former pharmaceutical executive known for raising the price of a lifesaving drug more than 40-fold, has been released from prison, where he had been serving a seven-year term ...
A federal judge has put a temporary ban on “pharma bro” Martin Shkreli from streaming or disseminating copies of a one-of-a-kind Wu-Tang Clan album that he purchased for $2 million in 2015.